{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+rosuvastatin", "query": { "intervention": "Placebo to match rosuvastatin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+rosuvastatin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T03:11:54.312Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07619131", "title": "A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Laroprovstat", "type": "DRUG" }, { "name": "Rosuvastatin 1", "type": "DRUG" }, { "name": "Rosuvastatin 2", "type": "DRUG" }, { "name": "Laroprovstat/Rosuvastatin 1", "type": "DRUG" }, { "name": "Placebo to match rosuvastatin", "type": "DRUG" }, { "name": "Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1", "type": "DRUG" }, { "name": "Laroprovstat/Rosuvastatin 2", "type": "DRUG" }, { "name": "Placebo to match Laroprovstat/Rosuvastatin 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 600, "start_date": "2026-08-12", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 77, "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619131" }, { "nct_id": "NCT06491550", "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD4144- Part A", "type": "DRUG" }, { "name": "Placebo- Part A", "type": "DRUG" }, { "name": "AZD4144- Part B", "type": "DRUG" }, { "name": "Placebo- Part B", "type": "DRUG" }, { "name": "Rosuvastatin and Furosemide- Part C", "type": "DRUG" }, { "name": "Rosuvastatin, Furosemide, and AZD4144 Part C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 91, "start_date": "2024-07-15", "completion_date": "2025-06-11", "has_results": false, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06491550" }, { "nct_id": "NCT00127218", "title": "High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Cardiovascular Disease" ], "interventions": [ { "name": "any statin", "type": "DRUG" }, { "name": "niacin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 145, "start_date": "2003-09", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00127218" }, { "nct_id": "NCT07216482", "title": "A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Enlicitide", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo for Enlicitide", "type": "DRUG" }, { "name": "Placebo for Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 996, "start_date": "2025-11-11", "completion_date": "2026-11-05", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Lancaster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216482" }, { "nct_id": "NCT01492361", "title": "A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Diseases" ], "interventions": [ { "name": "AMR101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Statin therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amarin Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 8179, "start_date": "2011-11", "completion_date": "2018-05", "has_results": true, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01492361" }, { "nct_id": "NCT01663402", "title": "ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LMT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 18924, "start_date": "2012-10", "completion_date": "2018-01-23", "has_results": true, "last_update_posted_date": "2019-03-18", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 273, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663402" }, { "nct_id": "NCT00249912", "title": "Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Lapaquistat acetate and rosuvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2005-10", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2012-05-24", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00249912" }, { "nct_id": "NCT00487136", "title": "Interaction Between ABT-335, Rosuvastatin and Warfarin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Warfarin", "type": "DRUG" }, { "name": "warfarin plus ABT-335 plus rosuvastatin 5 mg", "type": "DRUG" }, { "name": "warfarin plus ABT-335 plus rosuvastatin 20 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 45, "start_date": "2007-06", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2012-09-28", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487136" }, { "nct_id": "NCT00532311", "title": "Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Lapaquistat acetate and stable statin therapy", "type": "DRUG" }, { "name": "Stable statin therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 411, "start_date": "2007-07", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2016-06-22", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00532311" }, { "nct_id": "NCT06717269", "title": "A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "NX-5948", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 223, "start_date": "2024-11-30", "completion_date": "2026-05-01", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-01T03:11:54.312Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06717269" } ] }